Distinguished Research Fellow
Division Director of Biotechnology Incubation Center

EDUCATION AND POSITIONS HELD:

• Ph.D. Pharmacology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 1978
• Postdoctoral Fellow, Clinical Oncology Laboratory of NCI, NIH, 1977-1980
• Senior Staff Fellow, Biochemical Genetics Laboratory of NIH, 1980-1982
• Head of Immunology, Biogen S.A., Geneva, Switzerland, 1982-1986
• Senior Scientist, Biogen Research Corp. Cambridge, MA, 1986-1987
• Acting Chief, Immunology Section, Retrovirology Branch, Division of Blood & Blood Products, FDA,Bethesda, MD, 1987-1990
• Director of Molecular Immunology, Oncologix Inc. Gaithersburg, MD, 1990-1994
• Scientific Director, Assayland, Inc., Bethesda, MD, 1994-1997
• Research Fellow, Institute of Biological Chemistry, Academia Sinica, Taiwan, 1997-2006
• Director, Office of Public Affairs and Technology Transfer, Academia Sinica, Taiwan, 1997-2006, 2009-present
• Adjunct Research Fellow, Genomics Research Center, Academia Sinica, Taiwan, 2004-2006
• Adjunct Director, Biotechnology Incubation Center, Genomics Research Center, Academia Sinica,Taiwan, 2004-2006
• Adjunct Professor, National Chung Hsing University, Taiwan, 2006-2008
• Distinguished Investigator and Secretary General, National Health Research Institutes, Taiwan, 2006-2009
• Senior Advisor, President Office, Academia Sinica, Taiwan, 2006-present
• Distinguished Research Fellow, Genomics Research Center, Academia Sinica, Taiwan, 2009-present
• Director, Biotechnology Incubation Center, Genomics Research Center, Academia Sinica, Taiwan, 2009-present

PATENTS:

• Liang, S.-M., Peng, J.-M., and Liang, C.-M. Apoptosis-inducing polypeptides. US Patent No. 7700730 Granted, 2010
• Apoptosis-inducing polypeptides. US Patent No. 7488800 Granted, 2009
• Apoptosis-inducing polypeptides. US Patent No. 7323546 Granted, 2008
• Monoclonal antibodies specific for human thymidylate synthase. US Patent No. 6,221,620 Granted, 2001
• treatment of vascular leakage and related syndrome such as septic shock by administration of matrix metalloproteinase inhibitors. US Patent No. 5,866,570 Granted, 1999
• Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors. AU Patent No. 43,739,939 Granted, 1993
• Monoclonal antibodies specific for human thymidylate synthase. CA Patent No. 2,109,086 Granted, 1992

RESEARCH INTERESTS:

Dr. Liang's research interest is focusing primarily on exploring the biological functions and mechanism of action of biological active molecules for development of preventive and therapeutic medicines. He is particularly interested in the cellular events related to cytokines, cancer metastasis and apoptosis. Besides molecular and cellular biology studies, he also likes to utilize his broad experience in immunology, pharmacology, biochemistry, regulatory affairs, project management of research and development as well as patent filing, licensing and marketing, to contribute to the build-up of biotechnology industry in Taiwan.

SELECTED PUBLICATIONS:

• Huang CY, Liang CM, Chu CL, Peng JM, Liang SM, 2010, “A fibrillar form of fibronectin induces apoptosis by activating SHP-2 and stress fiber formation.”, Apoptosis : an international journal on programmed cell death, 15(8), 915-926. (SCI)
• Y.-C. Cheng, C.-M. Liang, Y.-P. Chen, I.-H. Tsai, C.-C. Kuo & S.-M.Liang, 2009, “F-spondin plays a critical role in murine neuroblastoma survival by maintaining IL-6 expression.”, J. Neurochem., 110(3), 947-955. (SCI)
• C.Y. Huang, C.Y.C.-M. Liang, C.L. Chu, & S.M. Liang, 2009, “Albumin fibrillization induces apoptosis via integrin/FAK/Akt pathway”, BMC Biotechnology, 9, 2. (SCI)
• G. Nagarajan, C. C. Kuo, C. M. Liang, C. M. Chen and S. M. Liang, 2007, “Effects of CpG-B ODN on the protein expression profile of swine PBMC”, Vet Res, 38(6), 795-808. (SCI)
• C. C. Kuo, C. M. Liang, C. Y. Lai and S. M. Liang, 2007, “Involvement of Heat Shock Protein (Hsp)90beta but Not Hsp90{alpha} in Antiapoptotic Effect of CpG-B Oligodeoxynucleotide”, J Immunol, 178(10), 6100-6108. (SCI)
• C. C. Kuo, S. M. Liang and C. M. Liang, 2006, “CpG-B oligodeoxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-xL and to decrease apoptosis-inducing factor translocation.”, J Biol Chem, 281(50), 38200-38207. (SCI)
• S. A. Kim, C. M. Liang, I. C. Cheng, Y. C. Cheng, M. T. Chiao, C. J. Tseng, F. Lee, M. H. Jong, M. H. Tao, N. S. Yang and S. M. Liang, 2006, “DNA vaccination against foot-and-mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity”, J Gene Med, 8(9), 1182-1191. (SCI)
• Kim, S.-A., Liang, C.-M., Chiao, M.-T., Cheng, I.-C., Lee, F., Jong, M.-H., Tao, M.-H., Tseng, C.J., Yang, N.-S., and Liang, S.-M., 2006, “DNA vaccination against foot-and-mouth disease via electroporation: Study of molecular approaches for enhancing VP1 antigenicity.”, J. Gene Med., 8(9), 1182-1191. (SCI)
• C. C. Kuo, W. T. Lin, C. M. Liang and S. M. Liang, 2006, “Class I and III Phosphatidylinositol 3'-Kinase Play Distinct Roles in TLR Signaling Pathway”, J Immunol, 176(10), 5943-5949. (SCI)
• Cheng-Chin Kuo, Chu-Wei Kuo , Chi-Ming Liang, Shu-Mei Liang, 2005, “A transcriptomic and proteomic analysis of the effect of CpG-ODN on human THP-1 monocytic leukemia cells”, Proteomics, 5(4), 894-906. (SCI)
• J. M. Peng, S. M. Liang and C. M. Liang, 2004, “VP1 of foot-and-mouth disease virus induces apoptosis via Akt signaling pathway”, J Biol Chem, 279(50), 52168-52174. (SCI)
• J. H. Wang, C. M. Liang, J. M. Peng, J. J. Shieh, M. H. Jong, Y. L. Lin, M. Sieber and S. M. Liang, 2003, “Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus”, Vaccine, 21, 3721-3729. (SCI)
• J. Pugin, M. C. Widmer, S. Kossodo, C. M. Liang, H. L. n. Preas and A. F. Suffredini, 1999, “Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators”, Am J Respir Cell Mol Biol, 20, 458-464.
• C. M. Liang, 1999, “Treatment of vascular leakage and related syndrome such as septic shock by administration of metalloproteinase inhibitors”, US patent, #5,866,570.
• P. G. Johnston, 1996, “Monoclonal antibodies specific for human thymidylate synthase”, US patent, 6,221,620.
• D. W. Visscher, M. Hoyhtya, S. K. Ottosen, C. M. Liang, F. H. Sarkar, J. D. Crissman and R. Fridman, 1994, “Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence”, Int J Cancer, 59, 339-344. (SCI)
• M. Hoyhtya, R. Fridman, D. Komarek, K. Porter Jordan, W. G. Stetler Stevenson, L. A. Liotta and C. M. Liang, 1994, “Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies”, Int J Cancer, 56, 500-505. (SCI)
• M. K. Bhat, C. Parkison, P. McPhie, C. M. Liang and S. Y. Cheng, 1993, “Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine”, Biochem Biophys Res Commun, 195, 385-392.
• S. P. Jiang, 1993, “Development of novel immunoassays to distinguish between the free and complexed forms of matrix metalloproteinase-2 (MMP-2)”, FASEB J, 7, 1211. (SCI)
• R. Fridman, R. E. Bird, M. Hoyhtya, M. Oelkuct, D. Komarek, C. M. Liang, M. L. Berman, L. A. Liotta, W. G. Stetler Stevenson and T. R. Fuerst, 1993, “Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme”, Biochem J, 289, 411-416. (SCI)